{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:03:16Z","timestamp":1775217796947,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12328-026-02282-8","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:35:09Z","timestamp":1771832109000},"page":"400-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of intestinal tumor formation during gilteritinib therapy that resolved without discontinuing the drug"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9944-6760","authenticated-orcid":false,"given":"Koji","family":"Oka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaharu","family":"Shikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Matsukage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2282_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264\u201378.","journal-title":"Cell"},{"key":"2282_CR2","first-page":"424","volume":"133","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. A review of FLT3 kinase inhibitors in acute myeloid leukemia. Blood. 2019;133:424\u201337.","journal-title":"Blood"},{"key":"2282_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective Inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicenter, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol. 2017;18:1061\u201375.","journal-title":"Lancet Oncol"},{"key":"2282_CR4","unstructured":"European Medicines Agency. Assessment report: Xospata. EMA\/545585\/2019. 2019."},{"key":"2282_CR5","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1007\/s00277-023-05392-2","volume":"102","author":"S Perrone","year":"2023","unstructured":"Perrone S, Imperatore S, Sucato G, Notarianni E, Corbingi A, Andriola C, et al. Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect. Ann Hematol. 2023;102:3025\u201330.","journal-title":"Ann Hematol"},{"key":"2282_CR6","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, Heuser M, Lee JH, Kim HJ, et al. Phase 3 trial of gilteritinib plus Azacitidine vs Azacitidine for newly diagnosed FLT3-mutated AML ineligible for intensive chemotherapy. Blood. 2022;140:1845\u201357.","journal-title":"Blood"},{"key":"2282_CR7","first-page":"1479","volume":"11","author":"L Gozzo","year":"2023","unstructured":"Gozzo L, Nardo A, Brancati S, Judica A, Duminuco A, Maugeri C, et al. Severe GI toxicity following the use of gilteritinib: a case series and analysis of postmarketing surveillance data. Healthc (Basel). 2023;11:1479.","journal-title":"Healthc (Basel)"},{"key":"2282_CR8","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.cgh.2020.04.069","volume":"19","author":"S Hamdeh","year":"2021","unstructured":"Hamdeh S, Micic D, Hanauer SB. Drug-induced colitis. Clin Gastroenterol Hepatol. 2021;19:1759\u201379.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2282_CR9","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/1535-7163.MCT-21-0071","volume":"20","author":"ME Zavorka Thomas","year":"2021","unstructured":"Zavorka Thomas ME, Lu X, Talebi Z, Jeon JY, Buelow DR, Gibson AA, et al. Gilteritinib inhibits glutamine uptake and utilization in FLT3-ITD\u2013positive AML. Mol Cancer Ther. 2021;20:2207\u201317.","journal-title":"Mol Cancer Ther"},{"key":"2282_CR10","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1021\/bm800146j","volume":"9","author":"CB Geer","year":"2008","unstructured":"Geer CB, Stasko NA, Rus IA, Lord ST, Schoenfisch MH. Influence of glutathione and its derivatives on fibrin polymerization. Biomacromolecules. 2008;9:1876\u201382.","journal-title":"Biomacromolecules"},{"key":"2282_CR11","doi-asserted-by":"publisher","first-page":"591872","DOI":"10.3389\/fonc.2020.585151","volume":"10","author":"K Suknuntha","year":"2020","unstructured":"Suknuntha K, Ramachandran A, Chaturvedi A, Kaushansky K, Deeg HJ, Papayannopoulou T. Megakaryocytic expansion in gilteritinib-treated acute myeloid leukemia patients is associated with AXL Inhibition. Front Oncol. 2020;10:591872.","journal-title":"Front Oncol"},{"key":"2282_CR12","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-09-528752","volume":"123","author":"JHM van der Meer","year":"2014","unstructured":"van der Meer JHM, van der Poll T, van \u2019t Veer C. TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis. Blood. 2014;123:2460\u20139.","journal-title":"Blood"},{"key":"2282_CR13","doi-asserted-by":"crossref","first-page":"AB102","DOI":"10.1016\/S0016-5107(04)02459-9","volume":"61","author":"NM Patel","year":"2005","unstructured":"Patel NM, Srinivas GN, Shukla A, et al. Nonsteroidal anti-inflammatory drug colopathy mimicking malignant masses of the colon: a report of three cases and review of the literature. Gastrointest Endosc. 2005;61:AB102.","journal-title":"Gastrointest Endosc"},{"key":"2282_CR14","doi-asserted-by":"publisher","first-page":"e01151","DOI":"10.14309\/crj.0000000000001151","volume":"10","author":"K Ho","year":"2023","unstructured":"Ho K, Garcia-Aguilar J, Nagao S, Jacobson I. Colonic mass after NSAID use and concerns for malignancy. ACG Case Rep J. 2023;10:e01151.","journal-title":"ACG Case Rep J"},{"key":"2282_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000511748","volume":"15","author":"A Baiomi","year":"2021","unstructured":"Baiomi A, Abbas H, Mehershahi S, Daniel M. Non-steroidal anti-inflammatory drugs: a rare cause of colonic mass. Case Rep Gastroenterol. 2021;15:395\u20139.","journal-title":"Case Rep Gastroenterol"},{"key":"2282_CR16","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jcmgh.2022.01.002","volume":"13","author":"D Meriwether","year":"2022","unstructured":"Meriwether D, Jones AE, Ashby JW, et al. Macrophage COX2 mediates efferocytosis, resolution reprogramming, and intestinal epithelial repair. Cell Mol Gastroenterol Hepatol. 2022;13:1095\u2013120.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2282_CR17","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s10620-008-0579-1","volume":"54","author":"X Zou","year":"2009","unstructured":"Zou X, Cao J, Yao Y, Liu W, Chen L. Endoscopic findings and clinicopathologic characteristics of ischemic colitis: a report of 85 cases. Dig Dis Sci. 2009;54:2009\u201315.","journal-title":"Dig Dis Sci"},{"key":"2282_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1097\/PAS.0000000000000438","volume":"39","author":"TS Khor","year":"2015","unstructured":"Khor TS, Lauwers GY, Odze RD, Srivastava A. Mass-forming\u2019 variant of ischemic colitis is a distinct entity with predilection for the proximal colon. Am J Surg Pathol. 2015;39:1275\u201381.","journal-title":"Am J Surg Pathol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02282-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:25:01Z","timestamp":1775215501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02282-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02282-8","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from the patient for this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}